Centessa Pharmaceuticals PLC

Centessa Pharmaceuticals — Investor Presentation (September 2024)

39 slides from Centessa Pharmaceuticals's investor presentation, Sep 10, 2024

  1. Slide 1: Corporate Overview

    Exhibit 99.2 Corporate Overview September 10, 2024

  2. Slide 2: Disclaimer and Forward Looking Statements

    2 DISCLAIMER AND FORWARD LOOKING STATEMENTS This presentation has been prepared by Centessa Pharmaceuticals plc (the “Company”) for planned clinical trials; our ability to obtain adequate financing, including through our financing facility informational purposes only and not for any other purpose. T

  3. Slide 3: Our Mission

    OUR MISSION Discovering and developing medicines that are transformational for patients Multiple potential blockbuster assets Ongoing momentum in 2024 with clinical milestones anticipated across our most advanced programs Strong balance sheet Centessa reported $294.8 million in cash, cash equivalent

  4. Slide 4: Our Most Advanced Potential First-in-Class/Best-in-Class Medicines for Patients

    Our Most Advanced Potential First-in-Class/Best-in-Class Medicines for Patients PRE- ASSET DISEASE/CONDITION MECHANISM CLINICAL PHASE 1 PHASE 2 REGISTRATIONAL SerpinPC Hemophilia B Activated Protein C Inhibitor ORX750 Sleep-Wake Disorders Orexin Receptor 2 (OX2R) Agonist NT1, NT2 & IH Excessive Dayt

  5. Slide 5: 2024 Driving Momentum: Anticipated Milestones

    OREXIN AGONIST PROGRAM ORX750 Plan to rapidly advance into Phase 2 studies in patients with NT1, NT2, and IH beginning in Q4 of 2024 ORX142 Preclinical data to be presented at Sleep Europe 2024 2024 Driving HEMOPHILIA PROGRAM Momentum SerpinPC ANTICIPATED MILESTONES PRESent-2 Part 1 interim analysis

  6. Slide 6: Orexin Agonist Program

    LockBody Orexin Agonist Hemophilia Technology Program Program Platform 6

  7. Slide 7: Orexin agonists have the potential to transform the standard of care

    Orexin agonists have the potential to transform the standard of care for individuals with sleep-wake disorders and excessive daytime sleepiness (EDS) across select disorders 7

  8. Slide 8: ORX750: Centessa's Lead OX2R Agonist for Sleep-Wake Disorders

    ORX750: Centessa’s Lead OX2R Agonist for Sleep-Wake Disorders (NT1, NT2 and IH) ORX750 Orexin agonists target the underlying cause of NT1 and have the potential to Highly potent, selective orexin treat EDS across multiple disorders receptor type 2 (OX2R) agonist 8 NT1 (narcolepsy type 1 ); NT2 (narc

  9. Slide 9: ORX750 a Potential Best-in-Class Oral OX2R Agonist

    ORX750 a Potential Best-in-Class Oral OX2R Agonist for the Treatment of Sleep-Wake Disorders (NT1, NT2 and IH) Highly potent, selective, Shown to restore normative Favorable safety and 2 1 novel OX2R agonist with wakefulness in acutely tolerability profile; No linear PK profile to support sleep depr

  10. Slide 10: ORX750 is a Highly Potent and Selective OX2R Agonist

    ORX750 is a Highly Potent and Selective OX2R Agonist 100 EC 0.11 nM for hOX2R 50 ORX750 75 9,800-fold selectivity vs. hOX1R at hOX2R Activation 50 (% total) OXA at Activation pattern was indistinguishable from OXA hOX2R 1 with lack of biased agonism 25 ORX750 No significant differences in OX2R poten

  11. Slide 11: ORX750 First-in-Human Healthy Volunteer Study

    PHASE 1 STUDY ORX750 First-in-Human Healthy Volunteer (HV) Study Phase 1 clinical study of ORX750: Evaluate the safety, tolerability and pharmacokinetics (PK) of single-ascending and multiple-ascending doses in healthy adult subjects In parallel Efficacy assessments are being performed using the Mai

  12. Slide 12: SAD Combined with Efficacy Assessment in Acutely Sleep-Deprived HV

    PHASE 1 STUDY SAD Combined with Efficacy Assessment in Acutely Sleep-Deprived HV PoC sleep study cohorts to assess efficacy of ORX750 by measuring sleep latency with the Maintenance of Wakefulness Test (MWT) and subjective sleepiness with the Karolinska Sleepiness Scale (KSS) in acutely sleep-depriv

  13. Slide 13: ORX750 Significantly Improved Mean Sleep Onset Latency at First Two Doses

    INTERIM PHASE 1 ORX750 Significantly Improved Mean Sleep Onset Latency (measured by MWT) at First Two Doses Compared to Placebo LS Mean Difference Compared Post Dose LS Mean (95% CI) To Placebo In Mean Sleep Onset Sleep Onset Latency (Minutes) Latency (95% CI) Estimate (95% CI) P-value ORX750 1.0 mg

  14. Slide 14: ORX750 Demonstrated a Favorable Safety and Tolerability Profile

    INTERIM PHASE 1 ORX750 Demonstrated a Favorable Safety and Tolerability Profile ORX750 ORX750 ORX750 Placebo 1.0 mg 2.0 mg 2.5 mg No observations of frequently (n=9) (n=9) (n=9) (n=9) reported on-target AEs associated Any TEAE, n (%) 3 (33) 4 (44) 3 (33) 2 (22) with OX2R agonists (i.e., urinary Rela

  15. Slide 15: Building a Multi-Asset Orexin Agonist Franchise

    Building a Multi-Asset Orexin Agonist Franchise ORX142 ORX750 Excessive Daytime Sleep-Wake Sleepiness (EDS) select neurological, neurodegenerative Disorders and psychiatric disorders NT1, NT2 & IH $10B+ $5B+ potential market potential market opportunity opportunity Centessa’s orexin pipeline also in

  16. Slide 16: Plan to rapidly advance ORX750 into Phase 2 studies

    Plan to rapidly advance ORX750 into Phase 2 studies in patients with NT1, NT2 and IH beginning in Q4 of 2024 ORX142 preclinical data to be presented at Sleep Europe 2024 16

  17. Slide 17: Hemophilia Program

    LockBody Orexin Agonist Hemophilia Technology Program Program Platform 17

  18. Slide 18: Hemophilia B: Large Growing Market with Unmet Need

    Hemophilia B: Large Growing Market with Unmet Need A safe, subcutaneous and effective treatment has the potential to transform care for hemophilia B No subcutaneous treatment option currently ~$2.6B+ 2 available for hemophilia B in the US Hemophilia B 1 Market Limited options for hemophilia B with 2

  19. Slide 19: SerpinPC Novel Mechanism of Action

    Novel mechanism of action SerpinPC has the potential to be a first-in-class 1 Showed significant reduction in bleeding subcutaneous therapy with a differentiated safety Shown to have a favorable safety and well profile for people with 1 tolerated profile to date; No thrombosis hemophilia B 1 observe

  20. Slide 20: SerpinPC: Novel Approach Designed to Prevent and Reduce Bleeding

    SerpinPC: Novel Approach Designed to Prevent and Reduce Bleeding SerpinPC Designed to reduce levels of circulating activated protein C (APC) 20 Prothrombinase

  21. Slide 21: Phase 2a Ongoing Study of SerpinPC in Hemophilia

    Phase 2a | Ongoing Study of SerpinPC in Hemophilia AP-0101 (NCT04073498) | An adaptive, first-in-human study to investigate the safety, tolerability, efficacy, and pharmacokinetics of SerpinPC in male persons with severe hemophilia ASH 2023 ASH 2022 Ongoing Phase 1/2a Part 1a Part 1b Part 2 Part 3 P

  22. Slide 22: SerpinPC Achieved a 96% Reduction in Median All-Bleeds ABR

    1 Phase 2a Part 5: SerpinPC Achieved a 96% Reduction in Median All-Bleeds ABR 1 AP-0101 Part 5 all bleed ABR at 1.2 mg/kg Q2W (n=20) Baseline Part 5 Medians 35.6 1.0 1 96% Reduction in Bleeding In Part 5, SerpinPC reduced median all-bleeds ABR to 1.0, a 96% reduction from prospective baseline. Subje

  23. Slide 23: SerpinPC Shown to Have Favorable Safety and Tolerability Profile

    SerpinPC Shown to Have Favorable Safety and Tolerability Profile to Date No observations of treatment-related adverse events in Part 5 Treatment Emergent Adverse Events Number of subjects (%) (TEAEs) n=20 All TEAEs (total 41 events) 16 (80%) Related to SerpinPC 0 Leading to discontinuation 1 (5%) Le

  24. Slide 24: SerpinPC's Potential for Differentiated Safety Profile

    SerpinPC’s Potential for Differentiated Safety Profile No observation of thrombosis 2 1 to date Mean D-dimer (ng/mg) No observations of treatment- related, non-transient elevations 2 in D-dimer across study For Part 5, 96% of D-dimer 2 results were <500 ng/ml Time since start of Part 2 (weeks) 1. Er

  25. Slide 25: SerpinPC Ongoing Global Registrational Program for Hemophilia B

    SerpinPC Ongoing Global Registrational Program for Hemophilia B Hemophilia B without inhibitors (n = 120) Primary Endpoint: ABR at 24 weeks Hemophilia B with inhibitors (n ≥ 12) >50 SITES Primary Endpoint: ABR at 24 weeks >15 COUNTRIES ABR is annualized bleeding rate. The primary endpoint for PRESen

  26. Slide 26: SerpinPC Registrational Program: Fast Track and Orphan Designations

    SerpinPC Ongoing Global Registrational Program for Hemophilia B Granted Fast Track designation by the FDA in May 2023 Granted Orphan Drug Designation by the FDA in Sept. 2022 26

  27. Slide 27: Potential Multi-Billion-Dollar Market Opportunities

    Potential Multi-Billion-Dollar Market Opportunities Hemophilia B Hemophilia A without inhibitors significant SerpinPC expansion opportunities Hemophilia B Rare bleeding with inhibitors disorders 27 Evaluate Pharma Analyst Consensus for 2023.

  28. Slide 28: LockBody Technology Platform

    Orexin Agonist Hemophilia LockBody Program Program Technology Platform 28

  29. Slide 29: Novel pharmacology combining tumor enrichment with activation of effector function

    Novel pharmacology combining tumor enrichment with activation of effector function LockBody Technology Platform aims to redefine Designed as single agent systemic immuno-oncology treatment treatment 1 Potential wide therapeutic index LB101 is an investigational agent that has not been approved by th

  30. Slide 30: MOA Locked Configuration LockBody LB101

    MOA Locked Configuration LockBody LB101 Conditionally tetravalent PD-L1xCD47 bispecific monoclonal antibody 30

  31. Slide 31: MOA Unlocked Configuration LockBody LB101

    MOA Unlocked Configuration LockBody LB101 Conditionally tetravalent PD-L1xCD47 bispecific monoclonal antibody 31

  32. Slide 32: Significant Tumor Regression Observed In-Vivo with LB101

    PRECLINICAL DATA Significant Tumor Regression Observed In-Vivo with LB101 Source: In vivo- 5 mg/kg of atezolizumab is equivalent to 8.5 mg/kg of LB101. Data presented at ASCO in June 2022. https://investors.centessa.com/static-files/2f9bffb4-97a6-4320-8885- 32 70f12aa4d036. MC38 hPD-L1+ syngeneic mo

  33. Slide 33: LB101 Well Tolerated in Non-Human Primates

    PRECLINICAL DATA Observed to be Well Tolerated in Non-Human Primates (NHPs) with LB101 Doses up to 50mg/kg No anemia/ No weight loss No change in red blood thrombocytopenia cell or hemoglobin 33 Source: In-vivo- LB101 delivered IV at 5, 20, 50mg/kg (q7d x 4) in non-human primates.

  34. Slide 34: LB101 is in an ongoing Phase 1/2a first-in-human clinical trial

    LB101 is in an ongoing Phase 1/2a first-in-human clinical trial 34

  35. Slide 35: 2024 Driving Momentum: Anticipated Milestones

    OREXIN AGONIST PROGRAM ORX750 Plan to rapidly advance into Phase 2 studies in patients with NT1, NT2, and IH beginning in Q4 of 2024 ORX142 Preclinical data to be presented at Sleep Europe 2024 2024 Driving HEMOPHILIA PROGRAM Momentum SerpinPC ANTICIPATED MILESTONES PRESent-2 Part 1 interim analysis

  36. Slide 36: Our Mission

    OUR MISSION Discovering and developing medicines that are transformational for patients Multiple potential blockbuster assets Ongoing momentum in 2024 with clinical milestones anticipated across our most advanced programs Strong balance sheet Centessa reported $294.8 million in cash, cash equivalent

  37. Slide 37: Centessa Pharmaceuticals

    « CENTESSA PHARMACEUTICALS

  38. Slide 38: ORX750 Increased Wakefulness and Suppressed Cataplexy in NT1 Mice

    PRECLINICAL DATA ORX750 Increased Wakefulness and Suppressed Cataplexy in NT1 Mice Wakefulness Latency to Cataplexy Maximal Maximal effect effect ORX750 (mg/kg, p.o.) ORX750 (mg/kg, p.o.) NT1 is Narcolepsy Type 1. % of Time Awake refers to time spent awake in the first 3 hours after oral dosing. ORX

  39. Slide 39: ORX750 Increased Wakefulness in Wild Type Mice

    PRECLINICAL DATA ORX750 Increased Wakefulness in Wild Type (WT) Mice Wake time (% during 2h post dose) ✱✱✱ 100 80 In WT mice (ie: orexin system 60 is intact and functional), wake time increased at 40 ≥ 1 mg/kg (lowest dose 20 tested) 0 0 1 3 10 ORX750 (mg/kg, p.o.) Data collected using PiezoSleep, i

Centessa Pharmaceuticals — Investor Presentation (September 2024) on 6ix